Clopidogrel resistance and its effect on clinical outcomes in acute coronary syndrome

IF 1.4 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Indian heart journal Pub Date : 2024-07-01 DOI:10.1016/j.ihj.2024.07.003

Heemanshu Lodhi , Keshavamurthy Ganapathy Bhat , Vivek Singh Guleria , Ratheesh Kumar Janardhana Pillai , Ribhu Goel , Nitin Sharma , Anuka Sharma , Varun Sharma

{"title":"Clopidogrel resistance and its effect on clinical outcomes in acute coronary syndrome","authors":"Heemanshu Lodhi , Keshavamurthy Ganapathy Bhat , Vivek Singh Guleria , Ratheesh Kumar Janardhana Pillai , Ribhu Goel , Nitin Sharma , Anuka Sharma , Varun Sharma","doi":"10.1016/j.ihj.2024.07.003","DOIUrl":null,"url":null,"abstract":"<div><h3>Aim</h3><p>The genetic polymorphism of CYP2C19 influences clopidogrel metabolism and resistance. Aim was to assess the association between CYP2C19 loss of function variation, clopidogrel resistance based on platelet reactivity units and clinical outcomes.</p></div><div><h3>Methods</h3><p>A total of 668 patients of Acute Coronary Sundrome (ACS) who underwent Percutaneous Coronary Intervention (PCI) were subjected to genetic screening and 143 patients undrewent platelet function test to study the association between drug metabolization and its effects based on platelet reactivity unit values.</p></div><div><h3>Results</h3><p>Clopidogrel resistance with CYP2C 19 loss of function variation was noted in 54.64% of patients. Clinical outcomes, such as target vessel revascularization, target lesion revascularization, in-stent restenosis, and stent thrombosis, were also studied.</p></div><div><h3>Conclusion</h3><p>CYP2C19 loss of function variation is strongly associated with clopidogrel resistance and adverse clinical outcomes.</p></div>","PeriodicalId":13384,"journal":{"name":"Indian heart journal","volume":"76 4","pages":"Pages 268-270"},"PeriodicalIF":1.4000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S001948322400155X/pdfft?md5=2de61b95e95ec8bc0b931d5592adf0a9&pid=1-s2.0-S001948322400155X-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian heart journal","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S001948322400155X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Aim

The genetic polymorphism of CYP2C19 influences clopidogrel metabolism and resistance. Aim was to assess the association between CYP2C19 loss of function variation, clopidogrel resistance based on platelet reactivity units and clinical outcomes.

Methods

A total of 668 patients of Acute Coronary Sundrome (ACS) who underwent Percutaneous Coronary Intervention (PCI) were subjected to genetic screening and 143 patients undrewent platelet function test to study the association between drug metabolization and its effects based on platelet reactivity unit values.

Results

Clopidogrel resistance with CYP2C 19 loss of function variation was noted in 54.64% of patients. Clinical outcomes, such as target vessel revascularization, target lesion revascularization, in-stent restenosis, and stent thrombosis, were also studied.

Conclusion

CYP2C19 loss of function variation is strongly associated with clopidogrel resistance and adverse clinical outcomes.

查看原文本刊更多论文

氯吡格雷耐药性及其对急性冠状动脉综合征临床疗效的影响

受 CYP2C19 基因多态性影响的氯吡格雷耐药性是研究接受经皮冠状动脉介入治疗（PCI）的急性冠状动脉综合征（ACS）患者临床疗效的一项挑战。共有 668 名患者接受了基因筛查，143 人进行了血小板功能检测，以研究药物代谢与基于血小板反应性单位值的药物作用之间的关联。在接受 PCI 治疗 6 个月后，54.64% 的患者出现了氯吡格雷耐药并伴有功能丧失变异。研究还对靶血管再通、靶病变再通、支架内再狭窄和支架血栓等临床结果进行了分析。这项研究强调了基因多态性、氯吡格雷耐药性和 PCI 后不良临床结果之间的关联。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Indian heart journal CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

2.60

自引率

6.70%

发文量

审稿时长

52 days

期刊介绍： Indian Heart Journal (IHJ) is the official peer-reviewed open access journal of Cardiological Society of India and accepts articles for publication from across the globe. The journal aims to promote high quality research and serve as a platform for dissemination of scientific information in cardiology with particular focus on South Asia. The journal aims to publish cutting edge research in the field of clinical as well as non-clinical cardiology - including cardiovascular medicine and surgery. Some of the topics covered are Heart Failure, Coronary Artery Disease, Hypertension, Interventional Cardiology, Cardiac Surgery, Valvular Heart Disease, Pulmonary Hypertension and Infective Endocarditis. IHJ open access invites original research articles, research briefs, perspective, case reports, case vignette, cardiovascular images, cardiovascular graphics, research letters, correspondence, reader forum, and interesting photographs, for publication. IHJ open access also publishes theme-based special issues and abstracts of papers presented at the annual conference of the Cardiological Society of India.